BeiGene Ltd.
- Country
- ๐บ๐ธUnited States
- Ownership
- Public
- Established
- 2010-01-01
- Employees
- 10K
- Market Cap
- $22.1B
- Website
- http://www.beigene.com
A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies
- Conditions
- Relapsed Non-Hodgkin LymphomaRefractory Non-Hodgkin LymphomaRelapsed Chronic Lymphocytic LeukemiaRefractory Chronic Lymphocytic LeukemiaRelapsed Follicular LymphomaRelapsed Marginal Zone LymphomaRelapse Diffuse Large B Cell LymphomaRelapsed Small Lymphocytic LymphomaRefractory Follicular LymphomaRefractory Marginal Zone Lymphoma
- Interventions
- First Posted Date
- 2023-04-25
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 85
- Registration Number
- NCT05828589
- Locations
- ๐ฆ๐บ
Linear Clinical Research, Nedlands, Western Australia, Australia
๐จ๐ณPeking University Third Hospital, Beijing, Beijing, China
๐จ๐ณHenan Cancer Hospital, Zhengzhou, Henan, China
Bioequivalence of a Zanubrutinib Tablet Compared to Capsules in Healthy Adult Participants
- First Posted Date
- 2023-03-14
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 58
- Registration Number
- NCT05767398
- Locations
- ๐บ๐ธ
Fortrea Clinical Research Unit, Dallas, Texas, United States
A Study to Evaluate the Safety and Efficacy of Zanubrutinib in Participants With Primary Membranous Nephropathy
- Conditions
- Interventions
- First Posted Date
- 2023-01-31
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 282
- Registration Number
- NCT05707377
- Locations
- ๐บ๐ธ
Carolina Nephrology, Spartanburg, South Carolina, United States
๐บ๐ธProlato Clinical Research Center, Houston, Texas, United States
๐จ๐ณZhejiang Provincial Peoples Hospital, Hangzhou, Zhejiang, China
A Study to Investigate the Antitumor Activity, Safety, Tolerability, and Pharmacokinetics of BGB-A445 in Combination With Tislelizumab in Participants With Select Advanced Solid Tumors.
- Conditions
- Interventions
- First Posted Date
- 2022-12-22
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 202
- Registration Number
- NCT05661955
- Locations
- ๐จ๐ณ
Peking University First Hospital, Beijing, Beijing, China
๐จ๐ณBeijing Cancer Hospital, Beijing, Beijing, China
๐จ๐ณFujian Cancer Hospital, Fuzhou, Fujian, China
Safety, Pharmacokinetics and Antitumor Activity of BGB-B167 Alone and in Combination With Tislelizumab in Participants With Solid Tumors in Chinese Participants
- First Posted Date
- 2022-12-09
- Last Posted Date
- 2023-11-29
- Lead Sponsor
- BeiGene
- Registration Number
- NCT05644626
Observational Study Evaluating the Efficacy and Safety of Zanubrutinib in Participants With Waldenstrรถm Macroglobulinemia
- First Posted Date
- 2022-12-07
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 111
- Registration Number
- NCT05640102
- Locations
- ๐บ๐ธ
Clearview Cancer Institute, Huntsville, Alabama, United States
๐บ๐ธMitchell Cancer Institute, Mobile, Alabama, United States
๐บ๐ธValkyrie Clinical Trials, Los Angeles, California, United States
A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer
- First Posted Date
- 2022-12-02
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 400
- Registration Number
- NCT05635708
- Locations
- ๐บ๐ธ
Massachusetts General Hospital, Boston, Massachusetts, United States
๐ฆ๐บChris Obrien Lifehouse, Camperdown, New South Wales, Australia
๐ฐ๐ทSeoul National University Bundang Hospital, Seongnamsi, Gyeonggi-do, Korea, Republic of
A Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer
- First Posted Date
- 2022-11-08
- Last Posted Date
- 2024-10-28
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 226
- Registration Number
- NCT05609370
- Locations
- ๐บ๐ธ
Usc Norris Comprehensive Cancer Center (Nccc), Los Angeles, California, United States
๐บ๐ธUt Health San Antonio Mays Cancer Center, San Antonio, Texas, United States
๐จ๐ณNanyang Central Hospital, Nanyang, Henan, China
Efficacy, Safety, and Pharmacodynamics of Tislelizumab Monotherapy and Multiple Tislelizumab-based Immunotherapy Combinations in Participants With Resectable Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-10-13
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 121
- Registration Number
- NCT05577702
- Locations
- ๐จ๐ณ
Hwa Mei Hospital, University of Chinese Academy of Sciences (Ningbo No Hospital), Ningbo, Zhejiang, China
๐จ๐ณThe First Affiliated Hospital of Wannan Medical College, Wuhu, Anhui, China
๐จ๐ณBeijing Cancer Hospital, Beijing, Beijing, China
Efficacy and Safety of Sitravatinib Plus Tislelizumab or Placebo Plus Tislelizumab Versus Placebo as Adjuvant Treatment in Participants With Hepatocellular Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2022-10-03
- Last Posted Date
- 2023-06-07
- Lead Sponsor
- BeiGene
- Registration Number
- NCT05564338